News

December 5, 2019

EIP Pharma Announces Presentation of Phase 2b Clinical Trial Results of Neflamapimod in Early-stage Alzheimer’s Disease at Clinical Trials in Alzheimer’s Disease (CTAD) meeting

Results demonstrate target engagement and proof-of-mechanism Boston, Mass., December 5, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor […]

Read More

November 7, 2019

EIP Pharma Announces Clinical Trial Results of REVERSE-SD, a Phase 2b Study of Neflamapimod in Early-stage Alzheimer’s Disease

Results demonstrate target engagement and proof-of-mechanism Boston, Mass., November 7, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the REVERSE-SD study of neflamapimod in early-stage Alzheimer’s disease met its secondary objectives of target engagement and proof-of-mechanism demonstrating statistically significant reductions relative to placebo in cerebrospinal fluid (CSF) levels of phospho-tau […]

Read More

EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)

Phase 2 clinical trial of neflamapimod in patients with mild-to-moderate DLB currently enrolling patients in the U.S. and the Netherlands Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need Boston, Mass., November 7, 2019 – EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that […]

Read More

View All News



Presentations




View All Presentations

About EIP

Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.

Contact Us